SCHEMBL17609664

SCHEMBL17609664

COCC(=O)Cn1c(=O)c2[nH]cnc2n(C)c1=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4A P27815 8/20 0.61
▸ PDE4B Q07343 8/20 0.61
▸ PDE4C Q08493 8/20 0.61
▸ PDE4D Q08499 8/20 0.61
▸ ADORA2B P29275 8/20 0.61
▸ ADORA2A P29274 7/20 0.61
▸ CFTR P13569 1/20 0.57
▸ ADORA3 P0DMS8 5/20 0.56
▸ ATAD2 Q6PL18 1/20 0.54
▸ TRPA1 O75762 1/20 0.53
▸ PIK3CD O00329 1/20 0.52
▸ ALPL P05186 1/20 0.52
▸ TMIGD3 P0DMS9 1/20 0.52
▸ ADORA1 P30542 1/20 0.52
▸ CYP2C19 P33261 1/20 0.52
▸ HIF1A Q16665 1/20 0.52
▸ LMNA P02545 1/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ MAPT P10636 1/20 0.51
▸ CHIT1 Q13231 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28325555 0.86 PDE4A (0.70) PDE4APDE4BPDE4CPDE4DADORA2B
SCHEMBL29528626 0.83 PDE4A (0.69) PDE4APDE4BPDE4CPDE4DADORA2B
SCHEMBL17609557 0.83 PDE4A (0.76) PDE4APDE4BPDE4CPDE4DADORA2B
SCHEMBL28325550 0.82 PDE4A (0.68) PDE4APDE4BPDE4CPDE4DADORA2B
Water SCHEMBL27884201 0.82 PDE4A (0.68) PDE4APDE4BPDE4CPDE4DADORA2B
SCHEMBL7608745 0.81 ADORA2B (0.71) PDE4APDE4BPDE4CPDE4DADORA2B
SCHEMBL30617922 0.81 PDE4A (0.66) PDE4APDE4BPDE4CPDE4DADORA2B
SCHEMBL30617921 0.81 PDE4A (0.66) PDE4APDE4BPDE4CPDE4DADORA2B
SCHEMBL7457855 0.80 ADORA2B (0.76) PDE4APDE4BPDE4CPDE4DADORA2B
SCHEMBL29081048 0.80 PDE4A (0.70) PDE4APDE4BPDE4CPDE4DADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3193880-B1 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL LILLY CO ELI (US) 2020-03-25 — — EP disclosed
EP-3193880-B1 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL LILLY CO ELI (US) 2020-03-25 — — EP disclosed
US-10519158-B2 Inhibiting the transient receptor potential A1 ion channel ELI LILLY AND COMPANY (US) 2019-12-31 — — US disclosed
US-10519158-B2 Inhibiting the transient receptor potential A1 ion channel ELI LILLY AND COMPANY (US) 2019-12-31 — — US disclosed
US-20190330212-A1 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL ELI LILLY AND COMPANY 2019-10-31 — — US disclosed
US-20190330212-A1 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL ELI LILLY AND COMPANY 2019-10-31 — — US disclosed
US-10221177-B2 Inhibiting the transient receptor potential A1 ion channel HYDRA BIOSCIENCES, INC. (US) 2019-03-05 — — US disclosed
US-10221177-B2 Inhibiting the transient receptor potential A1 ion channel HYDRA BIOSCIENCES, INC. (US) 2019-03-05 — — US disclosed
US-20170275285-A1 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL ELI LILLY AND COMPANY 2017-09-28 — — US disclosed
US-20170275285-A1 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL ELI LILLY AND COMPANY 2017-09-28 — — US disclosed
EP-3193880-A1 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL Hydra Biosciences, Inc. (US) 2017-07-26 — — EP disclosed
WO-2016044792-A1 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL HYDRA BIOSCIENCES, INC. (US) 2016-03-24 — — WO disclosed
WO-2016044792-A1 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL HYDRA BIOSCIENCES, INC. (US) 2016-03-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10519158-B2 Inhibiting the transient receptor potential A1 ion channel TRPV1, TRPA1, TRPV2 PDE4A 1232/4885PDE4B 1716/4885PDE4C 2092/4885
US-10221177-B2 Inhibiting the transient receptor potential A1 ion channel TRPV1, TRPA1, TRPV2 PDE4A 1232/4885PDE4B 1716/4885PDE4C 2092/4885
US-20170275285-A1 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL TRPV1, TRPA1, TRPV2 PDE4A 1232/4885PDE4B 1716/4885PDE4C 2092/4885
US-20190330212-A1 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL TRPV1, TRPA1, TRPV2 PDE4A 1232/4885PDE4B 1716/4885PDE4C 2092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback